Last mentioned: Mar 17, 2026
Market Peak
Projected valuation of $25.15 billion reached through global capacity expansion.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
Current Milestone
Market valuation hits significant mid-term growth targets as supply meets latent demand.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Infrastructure Investment
Major fractionators announce multi-billion dollar investments in automated collection centers.
Supply Recovery
Plasma collection volumes begin to stabilize following pandemic-era disruptions.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.